Idelalisib treatment is associated with improved cytopenias in patients with relapsed/refractory iNHL and CLL

Дата публикации: 27-08-2026 00:00:00

Idelalisib treatment is associated with improved cytopenias in patients with relapsed/refractory iNHL and CLL

Схожие новости

#	Наименование новости	Тональность	Информативность	Дата публикации
1	Second interim analysis of a phase 3 study of idelalisib plus rituximab (R) for relapsed chronic lymphocytic leukaemia (CLL): efficacy analysis in patient subpopulations with Del(17p) and other adverse prognostic factors	0	5.21	27-08-2026
2	Mezigdomide-Carfilzomib-Dexamethasone Prolongs PFS Compared with Carfilzomib-Dexamethasone at First Relapse in Patients with Relapsed Or Refractory Multiple Myeloma	0	5	09-07-2026
3	Talquetamab Plus Daratumumab and Pomalidomide and Talquetamab Plus Daratumumab Prolong PFS Among Previously Treated Patients with Relapsed Or Refractory Multiple Myeloma	0	5	02-07-2026
4	Ultralow-Dose IL 10–Expressing CAR T Cells in Relapsed/Refractory Diffuse Large B-Cell Lymphoma	0	14.62	23-07-2026
5	Successful treatment with gilteritinib for popliteal extramedullary relapse of FLT-3-ITD acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation : a case report and literature review	0	13.23	20-08-2026
6	Landmark NHS approval of cancer drugs offers new hope for children and adults with rare blood cancers	0	11.77	17-07-2026
7	Toripalimab Plus Chemotherapy for Recurrent or Metastatic Nasopharyngeal Carcinoma	0	13.22	28-11-2023
8	Chemotherapy-Free Regimen of Targeted Agent and Immunotherapeutic Superior to Imatinib and Chemotherapy Among Adult Patients with Ph-positive ALL	0	21.16	16-10-2026
9	GSK presents positive data for Mo-Rez in platinum-resistant ovarian cancer	0	19.5	23-10-2026
10	Pembrolizumab Plus Quad-Shot Radiotherapy for Recurrent, Unresectable, or Metastatic Head and Neck Cancer	0	8.64	01-08-2026

Классификация: Пресс-релизы. Схожих патентов: 0. Схожих новостей: 10. Тональность: 0. Информативность: 2.16. Источник: escholarship.org.